Effects of doxazosin and propranolol on A2A adenosine receptors in essential hypertension

Hypertension

Volumn 40, Issue 6, 2002, Pages 909-913

  Varani, Katia ^a   Manfredini, Roberto ^a   Iannotta, Valeria ^a   Pancaldi, Cecilia ^a   Cattabriga, Elena ^a   Uluoglu, Canan ^b   Borea, Pier Andrea ^a   Portaluppi, Francesco ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Adrenergic receptor blockers; Antihypertensive agents; Assays; Hypertension, essential; Receptors, adenosine

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE RECEPTOR; CYCLIC AMP; DOXAZOSIN; PROPRANOLOL; PROTEIN SUBUNIT;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BINDING ASSAY; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LYMPHOCYTE; MALE; NEUTROPHIL; PRIORITY JOURNAL;

ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); ADULT; ANTIHYPERTENSIVE AGENTS; BINDING, COMPETITIVE; BLOOD PRESSURE; BODY MASS INDEX; CYCLIC AMP; DIASTOLE; DOXAZOSIN; FEMALE; HUMANS; HYPERTENSION; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PROPRANOLOL; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; REFERENCE VALUES; SYSTOLE; TREATMENT OUTCOME; TRIAZINES; TRIAZOLES;

EID: 0036900096     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000039505.79741.15     Document Type: Article

References (23)

1. Neutel JM, Taylor SH, Smith DHG, Weber MA, Aepfelbacher FC. Doxazosin. In: Messerli FH, ed. Cardiovascular Drug Therapy, 2nd Ed. Philadelphia: WB Saunders; 1996:681-689.
2. Wessels F. Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension. Am Heart J. 1991;121(1 pt 2):299-303.
3. Carruthers G, Dessain P. Fodor G, Newman C, Palmer W, Sim D. Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension: The Alpha Beta Canada Trial Group. Am J Cardiol. 1993;71:575-581.
4. 2-adrenoceptor alterations in patients with essential hypertension are normalized after treatment with doxazosin but not propranolol. J Hypertens. 2000;18:217-221.
5. Prichard BN, Owens CW. Mode of action of β-adrenergic blocking drugs in hypertension. Clin Physiol Biochem. 1990;8(suppl 2):1-10.
6. Frishman WH, Lazar EJ. Reduction of mortality, sudden death and non-fatal reinfarction with β-adrenergic blockers in survivors of acute myocardial infarction: A new hypothesis regarding the cardioprotective action of β-adrenergic blockade. Am J Cardiol. 1990:66: 66G-70G.
7. Olsson G, Ryden L. Prevention of sudden death using β-blockers. Review of possible contributory actions. Circulation. 1991; 84(suppl 6):VI-33-VI-37.
8. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev. 1990;70:761-845.
9. Picano E, Abbracchio MP. Adenosine, the imperfect endogenous anti-ischemic cardio-neuroprotector. Brain Res Bull. 2000;52:75-82.
10. 3 receptor. Cancer Res. 1994;54:3521-3526.
11. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol. 1998;274(3 pt 2):R577-R595.
12. Kitakaze M, Hori M, Kamada T. Role of adenosine and its interaction with α-adrenoceptor activity in ischemic and reperfusion injury of the myocardium. Cardiovasc Res. 1993;27:18-27.
13. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M. α-Adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5′-nucleotidase activity. J Clin Invest. 1994; 93:2197-2205.
14. 1-adrenoceptor effects on reperfused ischaemic hearts: Comparison with phorbol ester. Br J Pharmacol. 1994;112:1007-1016.
15. + channels. Gen Pharmacol. 1998;30:351-356.
16. 1 receptor activation: Role of the K-ATP channel. J Pharmacol Exp Ther. 2000;294:770-777.
17. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
18. 2A adenosine receptors in human lymphocyte membranes by [3H]-SCH-58261 binding. Br J Pharmacol. 1997;122:386-392.
19. 2A adenosine receptors in human neutrophil membranes, Br J Pharmacol. 1998;123:1723-1731.
20. Munson PJ, Rodbard D. Ligand: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980;107: 220-239.
21. Amann FW, Bolli P, Kiowski W, Buhler FR. Enhanced α-adrenoreceptor-mediated vasoconstriction in essential hypertension. Hypertension. 1981;3(3 pt 2):1119-1123.
22. 2-adrenoceptor alterations in patients with essential hypertension. Br J Clin Pharmacol. 1999;47:167-172.
23. Kenakin T. Stimulus-response mechanisms. In: Kenakin T, ed. Pharmacologic Analysis of Drug-Receptor Interaction. New York: Raven Press; 1993:39-68.